# Atrandi Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atrandi-biosciences

- Industry: Biotechnology
- Headquarters: Vilnius, Lithuania
- Website: www.atrandi.com
- Total disclosed funding: $56M
- Latest round: Series A (Jan 27, 2026)
- Investors on record: 5

## About

Based in Vilnius, Lithuania, and founded in 2016 by CEO and co-founder Juozas Nainys, and Linas Mazutis, Atrandi Biosciences, Inc. formerly known as Droplet Genomics is a biotech firm that provides hardware systems, consumables, and software services to enable researchers to tap into the potential of droplet microfluidics technology for studying biological systems, as well as throughput screening applications. In January 2026, Atrandi Biosciences, Inc. raised EUR 21.26 million in series A funding from investors Lux Capital, GRIDS Capital, Metaplanet Holdings, Practica Capital, Vsquared Ventures.

The company provides a platform combined with droplet microfluidics technology, instruments, and consumables for medical researchers to perform complex biological system analysis and drug discovery research. The client base of Droplet Genomics includes universities, research institutes, and biotechnology companies located in Europe and the USA.

## Funding rounds

- Series A, Jan 27, 2026, $25M — Lux Capital, Practica Capital, Metaplanet Holdings, Vsquared Ventures, GRIDS Capital
- Series A, Feb 18, 2025, $25M — Lux Capital, Practica Capital, Metaplanet Holdings, Vsquared Ventures, GRIDS Capital
- Seed, Mar 23, 2023, $4.8M — Practica Capital, Metaplanet Holdings, Vsquared Ventures
- Seed, Jan 27, 2021, $1.2M — Practica Capital

## Investors

- Practica Capital (https://capitalatlas.ai/funds/practica-capital) — Seed, Series A
- Metaplanet Holdings (https://capitalatlas.ai/funds/metaplanet-holdings) — Seed, Series A
- Vsquared Ventures (https://capitalatlas.ai/funds/vsquared-ventures) — Seed, Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- GRIDS Capital — Series A